Avon Donates $20 Million to NCI for Cancer Research

Oncology NEWS InternationalOncology NEWS International Vol 10 No 12
Volume 10
Issue 12

BETHESDA, Maryland-The Avon Products Foundation has awarded $20 million to the National Cancer Institute to help support breast cancer research and expand early-phase clinical trials of promising techniques for prevention, diagnosis, and therapy.

BETHESDA, Maryland—The Avon Products Foundation has awarded $20 million to the National Cancer Institute to help support breast cancer research and expand early-phase clinical trials of promising techniques for prevention, diagnosis, and therapy.

The foundation also awarded $10 million each to the Massachusetts General Hospital/Harvard Comprehensive Cancer Center, the University of California, San Francisco Comprehensive Cancer Center, and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. It said the funds would be used at each institution to support biomedical research, clinical care for medically underserved women, and construction of new facilities focusing on breast cancer research and care.

Related Videos
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.
Experts on breast cancer
Experts on breast cancer
Experts on breast cancer
Hope S. Rugo, MD, an expert on breast cancer
Experts on breast cancer
Related Content